echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > New Immune Cell Therapy Drug-Enhanced Cell Therapy Detailed Explanation

    New Immune Cell Therapy Drug-Enhanced Cell Therapy Detailed Explanation

    • Last Update: 2022-08-30
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    PROTACs enhance TILs therapy


    Tumor-infiltrating lymphocytes (TILs) are a heterogeneous population of T cells that recognize a variety of endogenous tumor antigens but may develop an exhausted phenotype in the tumor microenvironment

    CRISPR Knockout PD-1 (Mol Ther Oncolytics.


    clinical research

    Advanced solid tumors (platinum-resistant ovarian cancer, endometrial cancer, cervical cancer) starting November 12, 2021

    NCT05107739 A Study of DeTIL-0255 in Adults With Advanced Malignancies


    ASCO Poster

    A phase 1 adoptive cell therapy using drug-enhanced, tumor-infiltrating lymphocytes, DeTIL-0255, in adults with advanced malignancies.


    Antibody drug enhances NK cell therapy


    Natural killer cells (NKs) are effector cells of the innate immune system that mount cytotoxic and effector responses to stress cells such as viral infections and tumor cytokines


    Celularity (CELU), headquartered in Florham Park, spun off from Celgene Cell Therapy in May 2016, raised $45 million in Series A financing in 2017, $21 million in Series B financing, and $100 million in Series B-1 financing in 2019.

    Clinical Trials


    HER2 antibody (trastuzumab) and other combination therapy for HER2+ solid tumors (NCT05207722, phase 1/2 clinical, 52 patients planned to be recruited)





    ASCO Abstract: https://ascopubs.

    Christopher Aled Chamberlain et al, Highly efficient PD-1-targeted CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T cell therapy.

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.